Skip to content

Clincal Observation on Modified Linggui Zhugan Decoction in Treating Obese Prediabetes with Phlegm-Dampness Constraint-Heat Syndrome

Clincal Observation on Modified Linggui Zhugan Decoction in Treating Obese Prediabetes with Phlegm-Dampness Constraint-Heat Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000701
Enrollment
Unknown
Registered
2026-03-24
Start date
2024-03-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

1:The control group received health education and lifestyle intervention (such as diet control and regular exercise).
2:the treatment group was given the modified Linggui Zhugan Decoction in addition to the intervention measures of the control group.

Sponsors

Beijing Hospital of Traditional Chinese Medicine, Yanqing Branch
Lead Sponsor

Eligibility

Sex/Gender
All
Age
36 Years to 66 Years

Inclusion criteria

Inclusion criteria: 1. Participants must meet the Western medical diagnostic criteria for prediabetes of type 2 diabetes mellitus, aged between 18 and 80 years, with no prior interventional treatment; 2. Conform to the diagnostic criteria for phlegm-dampness syndrome with internal heat; 3. Age range: 18–80 years; 4. Informed consent has been obtained.

Exclusion criteria

Exclusion criteria: 1) Current use of hypoglycemic agents or traditional Chinese patent medicines containing glucose-lowering ingredients; 2) Individuals with secondary hyperglycemia induced by medications or underlying diseases; 3) Patients complicated with other endocrine disorders, severe primary conditions (e.g., hepatic, renal, or hematopoietic system diseases), psychiatric disorders, or malignant tumors; 4) Women who are pregnant, lactating, or planning pregnancy; 5) Known or suspected hypersensitivity to the investigational drug; 6) Participation in other clinical trials within the past three months; 7) Use of any preparations containing ingredients identical to the trial drug within the preceding two weeks.

Design outcomes

Primary

MeasureTime frame
blood glucose;

Secondary

MeasureTime frame
weight;clinical symptoms;

Countries

China

Contacts

Public ContactLiJinze

Beijing Hospital of Traditional Chinese Medicine, Yanqing Branch

623592915@qq.com+86 131 2036 4844

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026